Leukemia

Best outcomes with transplantation, but non-transplant patients also benefited from quizartinib

Molecular or cytogenetic response at 3 months correlated with better survival

Newer therapies and strategies might show more promise for boosting survival

News, features, and commentary about cancer-related issues

Treatment with "pediatric-inspired protocols" improved event-free, relapse-free survival

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

Patients with higher diversity also had lower rates of acute graft-versus-host disease

News, features, and commentary about cancer-related issues

Quizartinib lands approval for newly diagnosed patients with FLT3-ITD-positive disease

Overweight, obese AYAs have lower event-free and overall survival, higher non-relapse mortality

News, features, and commentary about cancer-related issues

73% of patients with prior exposure to covalent BTK inhibitors responded

News, features, and commentary about cancer-related issues